- Home
- AIRJ vs OCGN Comparison
AIRJ vs OCGN Comparison
Compare AIRJ & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJ
- OCGN
- Stock Information
- Founded
- AIRJ 2018
- OCGN 2013
- Country
- AIRJ United States
- OCGN United States
- Employees
- AIRJ N/A
- OCGN N/A
- Industry
- AIRJ
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRJ
- OCGN Health Care
- Exchange
- AIRJ NYSE
- OCGN Nasdaq
- Market Cap
- AIRJ 256.6M
- OCGN 278.3M
- IPO Year
- AIRJ N/A
- OCGN N/A
- Fundamental
- Price
- AIRJ $4.64
- OCGN $1.13
- Analyst Decision
- AIRJ Strong Buy
- OCGN Strong Buy
- Analyst Count
- AIRJ 1
- OCGN 3
- Target Price
- AIRJ $12.00
- OCGN $6.00
- AVG Volume (30 Days)
- AIRJ 297.1K
- OCGN 8.0M
- Earning Date
- AIRJ 08-22-2025
- OCGN 08-07-2025
- Dividend Yield
- AIRJ N/A
- OCGN N/A
- EPS Growth
- AIRJ N/A
- OCGN N/A
- EPS
- AIRJ 0.86
- OCGN N/A
- Revenue
- AIRJ N/A
- OCGN $4,522,000.00
- Revenue This Year
- AIRJ N/A
- OCGN N/A
- Revenue Next Year
- AIRJ N/A
- OCGN N/A
- P/E Ratio
- AIRJ $5.39
- OCGN N/A
- Revenue Growth
- AIRJ N/A
- OCGN N/A
- 52 Week Low
- AIRJ $3.74
- OCGN $0.52
- 52 Week High
- AIRJ $11.75
- OCGN $1.98
- Technical
- Relative Strength Index (RSI)
- AIRJ 49.96
- OCGN 62.82
- Support Level
- AIRJ $4.60
- OCGN $0.91
- Resistance Level
- AIRJ $5.63
- OCGN $1.09
- Average True Range (ATR)
- AIRJ 0.42
- OCGN 0.08
- MACD
- AIRJ 0.02
- OCGN 0.01
- Stochastic Oscillator
- AIRJ 32.88
- OCGN 79.09
About AIRJ MONTANA TECHNOLOGIES CORP
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").